

TABLE 195: EPOETIN USE/BLOOD TRANSFUSION

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	EPOETIN USE			BLOOD TRANSFUSION		
			n	N	%	n	N	%
Buti et al., 2014 OPTIMIZE	1	(32) T12 PR24-48 RGT q8	29	371	8%	32	371	9%
		(33) T12 PR24-48 RGT q12	39	369	11%	31	369	8%
Feld et al., 2014 SAPPHIRE-I	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	1	473	0%	0	473	0%
Jacobson et al., 2011 ADVANCE	1	(1) PR48	NR			6	361	2%
		(32) T12 PR24-48 RGT q8				17	363	5%
Jacobson et al., 2014	1	(1) PR48	NR			3	130	2%
		(42) SIM12 PR24-48 RGT				3	264	1%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%	NR		
		(8) SOF8 + LDV8	0	20	0%			
		(9) SOF8 + LDV8 + RBV8	0	21	0%			
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	0	10	0%	NR		
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	0	25	0%	NR		
		(71) SOF24 + RBV (low dose) 24	0	25	0%			
Poordad et al., 2011 SPRINT2	1	(1) PR48	87	363	24%	2	363	1%
		(46) B24 PR28-48 RGT	159	368	43%	11	368	3%
Sulkowski et al., 2013-1+2 ^a	1	(1) PR48	1	22	5%	1	22	5%
		(39) T12 PR48 q8	3	38	8%	4	38	5%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	EPOETIN USE			BLOOD TRANSFUSION		
			n	N	%	n	N	%
Sulkowski et al., 2013	1	(1) PR48	6	34	18%	2	34	5%
		(50) B44 PR48	19	64	30%	4	64	5%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; NR = not reported; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.

^aData for ineligible participants who receive efavirenz-based antiretroviral and 1,125 mg of telaprevir every 8 hours are also included.